What are the dosing recommendations for Eliquis (apixaban) in non‑valvular atrial fibrillation, acute deep‑vein thrombosis/pulmonary embolism, extended secondary prevention, and postoperative prophylaxis after hip or knee replacement?

Eliquis (Apixaban) Dosing Recommendations

Non-Valvular Atrial Fibrillation

The standard dose of apixaban for stroke prevention in non-valvular atrial fibrillation is 5 mg orally twice daily, with dose reduction to 2.5 mg twice daily required when patients meet at least two of three specific criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1

Standard Dosing

• 5 mg orally twice daily for most patients with non-valvular AF and at least one stroke risk factor 2
• This dosing demonstrated superior efficacy to warfarin with lower rates of major bleeding and intracranial hemorrhage in the ARISTOTLE trial 2

Dose Reduction Criteria

• 2.5 mg orally twice daily when patients have ≥2 of the following 1, 2:
  • Age ≥80 years
  • Body weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL (approximately 133 μmol/L)

Renal Impairment Considerations

• Apixaban can be used with creatinine clearance (CrCl) as low as 15 mL/min, though safety and efficacy are not well-established below 30 mL/min 2
• The 2.5 mg twice daily dose applies when dose reduction criteria are met, regardless of whether this includes renal dysfunction 2
• Apixaban is not recommended in severe renal impairment (CrCl <15 mL/min) 2

---

Acute Deep Vein Thrombosis and Pulmonary Embolism (Treatment Phase)

For acute DVT/PE treatment, apixaban requires an initial loading dose of 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily for the remainder of treatment. 1, 2

Initial Treatment Regimen

• 10 mg orally twice daily for 7 days (loading phase) 2, 1
• Then 5 mg orally twice daily for at least 6 months total treatment duration 2, 1
• No dose reduction is specified for the treatment phase, even in patients with renal impairment 2

Treatment Duration

• Minimum 6 months for most patients with acute VTE 2
• Extended therapy beyond 6 months should be considered for unprovoked VTE or persistent risk factors 2

---

Extended Secondary Prevention (After Initial VTE Treatment)

After completing at least 6 months of initial anticoagulation for DVT or PE, the recommended dose for extended secondary prevention is 2.5 mg orally twice daily, which provides effective recurrence prevention with lower bleeding risk than full-dose anticoagulation. 1, 2

Extended Prevention Dosing

• 2.5 mg orally twice daily after ≥6 months of initial treatment 1, 2
• This reduced dose is specifically for secondary prevention, not acute treatment 2
• Alternative option: continue 5 mg twice daily if higher thrombotic risk is present, though 2.5 mg is generally preferred 2

Patient Selection for Extended Therapy

• Recommended for unprovoked VTE or VTE with persistent risk factors 2
• Extended anticoagulation should be reassessed at least annually 2
• The reduced-dose regimen (2.5 mg twice daily) is preferred over full-dose for extended prevention due to favorable risk-benefit profile [2, @26@]

---

Postoperative VTE Prophylaxis (Hip or Knee Replacement)

For thromboprophylaxis after major orthopedic surgery, apixaban is dosed at 2.5 mg orally twice daily, initiated 12-24 hours postoperatively, with duration depending on the type of surgery. 1, 2

Prophylaxis Regimen

• 2.5 mg orally twice daily 1, 2
• Initial dose: 12-24 hours after surgery (not before surgery, unlike some enoxaparin regimens) 1

Duration by Surgery Type

• Hip replacement: 35 days total duration 1, 2
• Knee replacement: 12 days total duration 1, 2

Perioperative Management

• No bridging anticoagulation is required when resuming apixaban postoperatively 1
• Adequate hemostasis must be established before restarting anticoagulation 1

---

Surgical Interruption Guidelines

Preoperative Discontinuation

• Low bleeding risk procedures: Stop apixaban 2 days before surgery (skip 2 doses) for normal renal function 2
• High bleeding risk procedures: Stop apixaban 3 days before surgery (skip 4 doses) for normal renal function 2, 1
• Moderate renal impairment (CrCl 30-50 mL/min): Extend discontinuation to 3-4 days depending on bleeding risk 2

Postoperative Resumption

• Resume apixaban when adequate hemostasis is established 1
• No bridging therapy is generally required during the 24-48 hour interruption period 1

---

Key Clinical Considerations

Missed Dose Management

• Take the missed dose as soon as possible on the same day 1
• Resume twice-daily dosing as scheduled 1
• Never double the dose to compensate for a missed dose 1

Drug Interactions

• Apixaban has multiple elimination pathways (only 27% renal), making it less susceptible to drug accumulation than predominantly renally cleared agents 2, 3
• Strong P-glycoprotein and CYP3A4 inhibitors may increase apixaban levels and should be considered when dosing 2

Common Pitfalls to Avoid

• Do not use AF dosing criteria for VTE treatment: The 2.5 mg twice daily dose for AF dose reduction is different from the 2.5 mg twice daily dose for extended VTE prevention 1
• Do not initiate apixaban before surgery for orthopedic prophylaxis: Unlike some enoxaparin regimens, apixaban starts postoperatively 1
• Do not use the 10 mg loading dose for anything other than acute VTE treatment: This high dose is only for the first 7 days of DVT/PE treatment 1